Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Membrane to cortex attachment determines different mechanical phenotypes in LGR5+ and LGR5- colorectal cancer cells

  • Conti, Sefora
  • Venturini, Valeria
  • Cañellas Socias, Adrià
  • Cortina Duran, Carme
  • Abenza, Juan F.
  • Stephan-Otto Attolini, Camille
  • Middendorp Guerra, Emily
  • Xu, Catherine K.
  • Li, Jia Hui
  • Rossetti, Leone
  • Stassi, Giorgio
  • Roca-Cusachs, Pere
  • Diz-Muñoz, Alba
  • Ruprecht, Verena
  • Guck, Jochen
  • Batlle Gómez, Eduard
  • Labernadie, Anna
  • Trepat, Xavier
Colorectal cancer (CRC) tumors are composed of heterogeneous and plastic cell populations, including a pool of cancer stem cells that express LGR5. Whether these distinct cell populations display different mechanical properties, and how these properties might contribute to metastasis is poorly understood. Using CRC patient derived organoids (PDOs), we find that compared to LGR5- cells, LGR5+ cancer stem cells are stiffer, adhere better to the extracellular matrix (ECM), move slower both as single cells and clusters, display higher nuclear YAP, show a higher survival rate in response to mechanical confinement, and form larger transendothelial gaps. These differences are largely explained by the downregulation of the membrane to cortex attachment proteins Ezrin/Radixin/Moesin (ERMs) in the LGR5+ cells. By analyzing single cell RNA-sequencing (scRNA-seq) expression patterns from a patient cohort, we show that this downregulation is a robust signature of colorectal tumors. Our results show that LGR5- cells display a mechanically dynamic phenotype suitable for dissemination from the primary tumor whereas LGR5+ cells display a mechanically stable and resilient phenotype suitable for extravasation and metastatic growth., The work was funded by the Generalitat de Catalunya (AGAUR 2021 SGR 01425 to X.T. and P.R-C., the CERCA Programme, and “ICREA Academia” award to P.R-C., AGAUR SGR-2021-001278 to E.B.); the Spanish Ministry for Science and Innovation MICCINN/FEDER (PID2021-128635NB-I00, MCIN/AEI/ 10.13039/501100011033 and “ERDF-EU A way of making Europe” to X.T., PID2019-110298GB-I00 to P.R-C., Mineco BES-2017-079847 to S.C., PID2020-117011GB-I00 to V.R., PID2020-119917RB-100 to E.B., PID2021-125212OA-I00 to A.L., RYC2020/029736/I to A.L.); the European Research Council (883739 Epifold to X.T., 884623 residualCRC to E.B., 101097753 MechanoSynth to P.R-C.), Fundació la Marató de TV3 (project 201903-30-31-32 to X.T. and E.B. and 201936-30-31 to P.R.-C.); European Commission (H2020-FETPROACT-01-2016-731957 to P.R-C. and X.T.); La Caixa Foundation (LCF/PR/HR20/52400004 and ID 100010434 under the agreement LCF/PR/HR20/52400004 to P.R-C. and X.T., LCF/BQ/PR18/11640001 to A.L.); The European Molecular Biology Laboratory (to A.D-M.); The EMBL Interdisciplinary Postdocs (EIPOD) fellowship under Marie Sklodowska-Curie Actions COFUND and Joachim Herz Foundation Add-on fellowship (to J.H.L); European Union’s Horizon EIC-ESMEA Pathfinder program under grant agreement (101046620 to V.R.); and The Peter and Traudl Engelhorn postdoctoral fellowship to C.K.X; European Union–- NextGenerationEU through the Italian Ministry of University and Research under PNRR–- M4C2-I1.3 Project PE_00000019““HEAL ITALIA (G.S.). IBEC, CRG and IRB are recipients of a Severo Ochoa Award of Excellence from the MINECO.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A plastic EMP1+ to LGR5+ cell state conversion as a bypass to KRASG12D pharmacologic inhibition in metastatic colorectal cancer

  • Centonze, Alessia
  • Novillo-Font, Meritxell
  • Novell, Mireia
  • Martí Renom, Marc A.
  • Batlle Gómez, Eduard
Inhibitors of the oncogene KRAS hold promise for treating metastatic colorectal cancer (mCRC). In this study, we show that a selective, covalent small-molecule inhibitor of the active (ON) conformation of RAS-G12D, RMC-9945, exerts durable disease control in preclinical colorectal cancer models of early liver metastasis, but its therapeutic activity was diminished in the advanced metastatic disease. RMC-9945-treated metastases underwent a transition from a poor prognosis-associated Emp1+ transcriptional state to a WNT-driven Lgr5+ stem cell-like state that withstands the absence of RAS-G12D activity. This cell state change occurred within hours of RAS(ON) inhibitor treatment through a shift in transcription factor usage that involved limited chromatin remodeling. Forced conversion of metastatic cells to the Lgr5+ state through RAS-G12D inhibition, followed by genetic ablation of this population, reduced metastatic burden and prolonged survival in a mouse mCRC model. Overall, these preclinical findings demonstrate a central role for oncogenic KRAS in governing cellular plasticity in mCRC. Significance: We show that inhibition of oncogenic KRAS in preclinical models of advanced mCRC exerts a limited benefit, primarily due to the reversion of tumor cells to a stem cell-like state. Our findings highlight the context-dependent effects of oncogenic KRAS mutations and underscore cell plasticity as a therapeutic opportunity. See related commentary by Eng and Yilmaz et al., p. 201., This research has also been funded by ERC advanced grants 884623 (residualCRC), La Caixa Foundation (HR24_00447), Ministerio de Ciencia e Innovación (PID2023-153116OB-I00), Persist_Seq consortium (IMI), La Generalitat de Catalunya (2021 SGR 001278) and CRC STARS (GEACC248909TABE, funded by CRUK-AECC). A. Centonze is supported by EMBO postdoctoral fellowship (ALTF 61-2023). A. Barbachano is supported by CIBERONC. The A. Muñoz laboratory is funded by MICINN (PID22-136729OB-I00). M.A. Marti-Renom and M. Novillo-Font acknowledge support by the Spanish Ministerio de Ciencia e Innovación (PID2023-151484NB-I00 and FPU20/05004, respectively). M.A. Marti-Renom also acknowledges support from Generalitat de Catalunya (2021-SGR-01127).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Five latent factors underlie response to immunotherapy

  • Usset, Joseph
  • Rosendahl Huber, Axel
  • Andrianova, Maria A.
  • Batlle Gómez, Eduard
  • Carles, Joan
  • Cuppen, Edwin
  • Elez, Elena
  • Felip, Enriqueta
  • Gómez Rey, Marina
  • Lo Giacco, Deborah
  • Martínez Jiménez, Francisco
  • Muñoz Couselo, Eva
  • Siu, Lillian L.
  • Tabernero Cartula, Josep
  • Vivancos Prellezo, Ana
  • Muiños, Ferran
  • González-Pérez, Abel
  • López Bigas, Núria
Only a subset of patients treated with immune checkpoint inhibitors (CPIs) respond to the treatment, and distinguishing responders from non-responders is a major challenge. Many proposed biomarkers of CPI response and survival probably represent alternative measurements of the same aspects of the tumor, its microenvironment or the host. Thus, we currently ignore how many truly independent biomarkers there are. With an unbiased analysis of genomics, transcriptomics and clinical data of a cohort of patients with metastatic tumors (n = 479), we discovered five orthogonal latent factors: tumor mutation burden, T cell effective infiltration, transforming growth factor-beta activity in the microenvironment, prior treatment and tumor proliferative potential. Their association with CPI response and survival was observed across all tumor types and validated across six independent cohorts (n = 1,491). These five latent factors constitute a frame of reference to organize current and future knowledge on biomarkers of CPI response and survival., We wish to acknowledge the contribution of patients, families and biomedical researchers who shared, processed and sequenced the data used in the study. This publication and the underlying study have been made possible partly based on the data that HMF has made available. We also acknowledge the use of data from the INSPIRE clinical trial (NCT02644369) and data obtained from patients presented at the VHIO. N.L.-B. acknowledges funding from the European Research Council (ERC; consolidator grant 682398). This project has received funding from the European Union’s Horizon program HORIZON-HLTH-2021-CARE-05-02 for the project CGI-Clinics under grant agreement no. 101057509. E.B. receives support from Generalitat de Catalunya (2021 SGR 001278) and ERC Advanced Grant 884623. The Institute for Research in Biomedicine Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and an Excellence Institutional grant by the Asociacion Española contra el Cancer and is supported by CERCA (Generalitat de Catalunya).
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Overcoming TGFβ-mediated immune evasion in cancer

  • Tauriello, Daniele V. F.
  • Sancho, Elena
  • Batlle, Eduard
This Review discusses the context-dependent functions of transforming growth factor-beta (TGF beta) with regard to the composition and behaviour of different cell populations in the tumour immune microenvironment, as well as emerging data that demonstrate that TGF beta inhibition can restore cancer immunity. Transforming growth factor-beta (TGF beta) signalling controls multiple cell fate decisions during development and tissue homeostasis; hence, dysregulation of this pathway can drive several diseases, including cancer. Here we discuss the influence that TGF beta exerts on the composition and behaviour of different cell populations present in the tumour immune microenvironment, and the context-dependent functions of this cytokine in suppressing or promoting cancer. During homeostasis, TGF beta controls inflammatory responses triggered by exposure to the outside milieu in barrier tissues. Lack of TGF beta exacerbates inflammation, leading to tissue damage and cellular transformation. In contrast, as tumours progress, they leverage TGF beta to drive an unrestrained wound-healing programme in cancer-associated fibroblasts, as well as to suppress the adaptive immune system and the innate immune system. In consonance with this key role in reprogramming the tumour microenvironment, emerging data demonstrate that TGF beta-inhibitory therapies can restore cancer immunity. Indeed, this approach can synergize with other immunotherapies - including immune checkpoint blockade - to unleash robust antitumour immune responses in preclinical cancer models. Despite initial challenges in clinical translation, these findings have sparked the development of multiple therapeutic strategies that inhibit the TGF beta pathway, many of which are currently in clinical evaluation.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Overcoming TGFβ-mediated immune evasion in cancer

  • Tauriello, Daniele V. F.
  • Sancho, Elena
  • Batlle, Eduard
This Review discusses the context-dependent functions of transforming growth factor-beta (TGF beta) with regard to the composition and behaviour of different cell populations in the tumour immune microenvironment, as well as emerging data that demonstrate that TGF beta inhibition can restore cancer immunity. Transforming growth factor-beta (TGF beta) signalling controls multiple cell fate decisions during development and tissue homeostasis; hence, dysregulation of this pathway can drive several diseases, including cancer. Here we discuss the influence that TGF beta exerts on the composition and behaviour of different cell populations present in the tumour immune microenvironment, and the context-dependent functions of this cytokine in suppressing or promoting cancer. During homeostasis, TGF beta controls inflammatory responses triggered by exposure to the outside milieu in barrier tissues. Lack of TGF beta exacerbates inflammation, leading to tissue damage and cellular transformation. In contrast, as tumours progress, they leverage TGF beta to drive an unrestrained wound-healing programme in cancer-associated fibroblasts, as well as to suppress the adaptive immune system and the innate immune system. In consonance with this key role in reprogramming the tumour microenvironment, emerging data demonstrate that TGF beta-inhibitory therapies can restore cancer immunity. Indeed, this approach can synergize with other immunotherapies - including immune checkpoint blockade - to unleash robust antitumour immune responses in preclinical cancer models. Despite initial challenges in clinical translation, these findings have sparked the development of multiple therapeutic strategies that inhibit the TGF beta pathway, many of which are currently in clinical evaluation.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A plastic EMP1+ to LGR5+ cell state conversion as a bypass to KRASG12D pharmacologic inhibition in metastatic colorectal cancer

  • Centonze, Alessia
  • Novillo-Font, Meritxell
  • Novell, Mireia
  • Martí Renom, Marc A.
  • Batlle Gómez, Eduard
Inhibitors of the oncogene KRAS hold promise for treating metastatic colorectal cancer (mCRC). In this study, we show that a selective, covalent small-molecule inhibitor of the active (ON) conformation of RAS-G12D, RMC-9945, exerts durable disease control in preclinical colorectal cancer models of early liver metastasis, but its therapeutic activity was diminished in the advanced metastatic disease. RMC-9945-treated metastases underwent a transition from a poor prognosis-associated Emp1+ transcriptional state to a WNT-driven Lgr5+ stem cell-like state that withstands the absence of RAS-G12D activity. This cell state change occurred within hours of RAS(ON) inhibitor treatment through a shift in transcription factor usage that involved limited chromatin remodeling. Forced conversion of metastatic cells to the Lgr5+ state through RAS-G12D inhibition, followed by genetic ablation of this population, reduced metastatic burden and prolonged survival in a mouse mCRC model. Overall, these preclinical findings demonstrate a central role for oncogenic KRAS in governing cellular plasticity in mCRC. Significance: We show that inhibition of oncogenic KRAS in preclinical models of advanced mCRC exerts a limited benefit, primarily due to the reversion of tumor cells to a stem cell-like state. Our findings highlight the context-dependent effects of oncogenic KRAS mutations and underscore cell plasticity as a therapeutic opportunity. See related commentary by Eng and Yilmaz et al., p. 201., This research has also been funded by ERC advanced grants 884623 (residualCRC), La Caixa Foundation (HR24_00447), Ministerio de Ciencia e Innovación (PID2023-153116OB-I00), Persist_Seq consortium (IMI), La Generalitat de Catalunya (2021 SGR 001278) and CRC STARS (GEACC248909TABE, funded by CRUK-AECC). A. Centonze is supported by EMBO postdoctoral fellowship (ALTF 61-2023). A. Barbachano is supported by CIBERONC. The A. Muñoz laboratory is funded by MICINN (PID22-136729OB-I00). M.A. Marti-Renom and M. Novillo-Font acknowledge support by the Spanish Ministerio de Ciencia e Innovación (PID2023-151484NB-I00 and FPU20/05004, respectively). M.A. Marti-Renom also acknowledges support from Generalitat de Catalunya (2021-SGR-01127).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Five latent factors underlie response to immunotherapy

  • Usset, Joseph
  • Rosendahl Huber, Axel
  • Andrianova, Maria A.
  • Batlle Gómez, Eduard
  • Carles, Joan
  • Cuppen, Edwin
  • Elez, Elena
  • Felip, Enriqueta
  • Gómez Rey, Marina
  • Lo Giacco, Deborah
  • Martínez Jiménez, Francisco
  • Muñoz Couselo, Eva
  • Siu, Lillian L.
  • Tabernero Cartula, Josep
  • Vivancos Prellezo, Ana
  • Muiños, Ferran
  • González-Pérez, Abel
  • López Bigas, Núria
Only a subset of patients treated with immune checkpoint inhibitors (CPIs) respond to the treatment, and distinguishing responders from non-responders is a major challenge. Many proposed biomarkers of CPI response and survival probably represent alternative measurements of the same aspects of the tumor, its microenvironment or the host. Thus, we currently ignore how many truly independent biomarkers there are. With an unbiased analysis of genomics, transcriptomics and clinical data of a cohort of patients with metastatic tumors (n = 479), we discovered five orthogonal latent factors: tumor mutation burden, T cell effective infiltration, transforming growth factor-beta activity in the microenvironment, prior treatment and tumor proliferative potential. Their association with CPI response and survival was observed across all tumor types and validated across six independent cohorts (n = 1,491). These five latent factors constitute a frame of reference to organize current and future knowledge on biomarkers of CPI response and survival., We wish to acknowledge the contribution of patients, families and biomedical researchers who shared, processed and sequenced the data used in the study. This publication and the underlying study have been made possible partly based on the data that HMF has made available. We also acknowledge the use of data from the INSPIRE clinical trial (NCT02644369) and data obtained from patients presented at the VHIO. N.L.-B. acknowledges funding from the European Research Council (ERC; consolidator grant 682398). This project has received funding from the European Union’s Horizon program HORIZON-HLTH-2021-CARE-05-02 for the project CGI-Clinics under grant agreement no. 101057509. E.B. receives support from Generalitat de Catalunya (2021 SGR 001278) and ERC Advanced Grant 884623. The Institute for Research in Biomedicine Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and an Excellence Institutional grant by the Asociacion Española contra el Cancer and is supported by CERCA (Generalitat de Catalunya).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Membrane to cortex attachment determines different mechanical phenotypes in LGR5+ and LGR5- colorectal cancer cells

  • Conti, Sefora
  • Venturini, Valeria
  • Cañellas Socias, Adrià
  • Cortina Duran, Carme
  • Abenza, Juan F.
  • Stephan-Otto Attolini, Camille
  • Middendorp Guerra, Emily
  • Xu, Catherine K.
  • Li, Jia Hui
  • Rossetti, Leone
  • Stassi, Giorgio
  • Roca-Cusachs, Pere
  • Diz-Muñoz, Alba
  • Ruprecht, Verena
  • Guck, Jochen
  • Batlle Gómez, Eduard
  • Labernadie, Anna
  • Trepat, Xavier
Colorectal cancer (CRC) tumors are composed of heterogeneous and plastic cell populations, including a pool of cancer stem cells that express LGR5. Whether these distinct cell populations display different mechanical properties, and how these properties might contribute to metastasis is poorly understood. Using CRC patient derived organoids (PDOs), we find that compared to LGR5- cells, LGR5+ cancer stem cells are stiffer, adhere better to the extracellular matrix (ECM), move slower both as single cells and clusters, display higher nuclear YAP, show a higher survival rate in response to mechanical confinement, and form larger transendothelial gaps. These differences are largely explained by the downregulation of the membrane to cortex attachment proteins Ezrin/Radixin/Moesin (ERMs) in the LGR5+ cells. By analyzing single cell RNA-sequencing (scRNA-seq) expression patterns from a patient cohort, we show that this downregulation is a robust signature of colorectal tumors. Our results show that LGR5- cells display a mechanically dynamic phenotype suitable for dissemination from the primary tumor whereas LGR5+ cells display a mechanically stable and resilient phenotype suitable for extravasation and metastatic growth., The work was funded by the Generalitat de Catalunya (AGAUR 2021 SGR 01425 to X.T. and P.R-C., the CERCA Programme, and “ICREA Academia” award to P.R-C., AGAUR SGR-2021-001278 to E.B.); the Spanish Ministry for Science and Innovation MICCINN/FEDER (PID2021-128635NB-I00, MCIN/AEI/ 10.13039/501100011033 and “ERDF-EU A way of making Europe” to X.T., PID2019-110298GB-I00 to P.R-C., Mineco BES-2017-079847 to S.C., PID2020-117011GB-I00 to V.R., PID2020-119917RB-100 to E.B., PID2021-125212OA-I00 to A.L., RYC2020/029736/I to A.L.); the European Research Council (883739 Epifold to X.T., 884623 residualCRC to E.B., 101097753 MechanoSynth to P.R-C.), Fundació la Marató de TV3 (project 201903-30-31-32 to X.T. and E.B. and 201936-30-31 to P.R.-C.); European Commission (H2020-FETPROACT-01-2016-731957 to P.R-C. and X.T.); La Caixa Foundation (LCF/PR/HR20/52400004 and ID 100010434 under the agreement LCF/PR/HR20/52400004 to P.R-C. and X.T., LCF/BQ/PR18/11640001 to A.L.); The European Molecular Biology Laboratory (to A.D-M.); The EMBL Interdisciplinary Postdocs (EIPOD) fellowship under Marie Sklodowska-Curie Actions COFUND and Joachim Herz Foundation Add-on fellowship (to J.H.L); European Union’s Horizon EIC-ESMEA Pathfinder program under grant agreement (101046620 to V.R.); and The Peter and Traudl Engelhorn postdoctoral fellowship to C.K.X; European Union–- NextGenerationEU through the Italian Ministry of University and Research under PNRR–- M4C2-I1.3 Project PE_00000019““HEAL ITALIA (G.S.). IBEC, CRG and IRB are recipients of a Severo Ochoa Award of Excellence from the MINECO.